Thymosin Alpha-1 in Canada: Research Guide (2026)
For laboratory research use only. Nothing on this page is medical advice, and no compound discussed here is offered for human use. Thymosin alpha-1 has never been an authorised drug in Canada.
What is thymosin alpha-1?
Thymosin alpha-1 (TA-1) is a 28-amino-acid peptide fragment of prothymosin alpha, first isolated in the 1970s from thymosin fraction 5 — a thymus-gland extract characterised by Allan Goldstein’s laboratory. The thymus is where T-cells mature, and TA-1 is the fraction-5 component that drew the most sustained research attention: it appears throughout the immunology literature as an immune-signalling modulator, studied for how it influences T-cell maturation, dendritic-cell activation and natural-killer-cell activity rather than for crudely “boosting” any one immune readout.
Two things give TA-1 an unusual profile among research peptides. First, a pharmaceutical form of it exists: thymalfasin (brand name Zadaxin) has been approved in dozens of countries — though never in Canada or the United States — which means TA-1 carries a real human clinical literature. Second, TA-1 became the centre of a live regulatory story in the US: the FDA moved to restrict pharmacy compounding of it, which sharply changed how researchers and clinics there can access the compound. This guide covers the research picture, the Canadian regulatory status, the TB-500 confusion that follows this peptide everywhere, and what to verify before sourcing research-grade material.
Class and mechanism
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate, or safe for a person.
TA-1 is classified as a thymic peptide / immunomodulator. The mechanisms discussed most often in the published work involve signalling through pattern-recognition receptors — notably Toll-like receptor pathways on dendritic cells — with downstream effects reported on T-cell differentiation, natural-killer-cell activity and the balance of pro- and anti-inflammatory signalling. The literature tends to describe TA-1 as a modulator rather than a stimulant: in laboratory models it has been reported to support immune responses in some settings and to temper excessive inflammatory signalling in others. Those are observations from cell and animal models and from trials of the authorized drug product abroad — not claims about research material.
The research literature
TA-1 appears in published research across several threads: infection and vaccine-adjuvant models (including the hepatitis B and C programs that supported thymalfasin’s approvals abroad), immunosenescence — how immune signalling changes with age, oncology-adjuvant literature where TA-1 was studied alongside other therapies, and sepsis and critical-illness trials, including large studies in China where the drug product is widely used. A comprehensive 2020 review (Dominari et al.) collects this record. The important caveat is the same one that applies to tesamorelin: the clinical evidence belongs to the authorized drug product under its conditions of use in the countries where it is approved. It does not transfer to research vials, and no equivalence is implied.
Thymosin alpha-1 vs TB-500: not the same family
The single most common confusion around this peptide. TA-1 is an alpha-thymosin; TB-500 is a synthetic version of thymosin beta-4 — a different peptide from a different family with a different research profile. TA-1 appears in immune-signalling research; TB-4/TB-500 appears in tissue-repair, actin-binding and cell-migration research. They are not interchangeable in any research design, and “thymosin” on a label is not enough information — the suffix is the substance. Quantum stocks both: see the TB-500 product page and the healing & recovery research guide for the beta-4 side of the family.
Regulatory status in Canada (and the US story)
In Canada, thymosin alpha-1 has never been an authorised drug. A search of Health Canada’s Drug Product Database returns no product containing thymosin alpha-1 or thymalfasin (verified September 2026) — no DIN, no prescription product, nothing to fill at a pharmacy. Zadaxin’s approvals exist abroad, not here. In Canada, TA-1 may be sold only as a research-use-only laboratory chemical.
The United States is where the regulatory picture recently moved. TA-1 was for years accessible there through compounding pharmacies. Following a 2024 advisory-committee review, the FDA declined to place thymosin alpha-1 on the list of substances that pharmacies may compound, and it is not an FDA-approved drug — which has effectively been closing off the US compounded route. That decision is one reason search interest in the compound has grown; it does not change anything in Canada, where the compound was never available as a medicine in the first place. Our guide to peptide legality in Canada covers the wider framework.
Purity and the COA question
Because TA-1 is sold as a research material rather than a regulated pharmaceutical, the meaningful quality question is what is actually in the vial. Quantum’s standard is a per-batch Certificate of Analysis — HPLC purity (target ≥99%) with mass-spectrometry identity confirmation from an independent Canadian laboratory, with the batch number printed on the vial. Batch certificates are published on the lab results hub as each batch completes independent testing — check there for the current Thymosin Alpha-1 batch before purchasing, and see the certificate of analysis hub for how to read one. For any research use, per-batch verification matters more than anything a supplier says about itself.
Where to buy thymosin alpha-1 in Canada
Quantum Peptides supplies Thymosin Alpha-1 as a 10mg lyophilized research vial, batch-coded, shipping domestically from Edmonton — see the Thymosin Alpha-1 product page for current stock. The supplied format is dry lyophilized peptide that a laboratory reconstitutes for its own protocols; pre-mixed pens sold elsewhere are different preparations. For research use only — not for human consumption. New to sourcing? Start with how to buy research peptides in Canada and how to verify a legit supplier.
Frequently asked questions
Can you buy thymosin alpha-1 in Canada?
Yes — as a research-use-only laboratory material. It is not an approved drug in Canada and is not sold for human consumption. Quantum supplies a 10mg lyophilized research vial.
Is thymosin alpha-1 the same as Zadaxin?
Zadaxin is a prescription drug product (active ingredient: thymalfasin, a pharmaceutical form of thymosin alpha-1) approved in dozens of countries — but never in Canada or the US. A research vial is not that product and is not represented as interchangeable with it; the clinical evidence belongs to the authorized drug under its conditions of use.
Do you need a prescription for thymosin alpha-1 in Canada?
There is no prescription to require: Health Canada’s Drug Product Database lists no product containing thymosin alpha-1 or thymalfasin (verified September 2026). It exists in Canada only as a research chemical for laboratory use.
What is the difference between thymosin alpha-1 and TB-500?
Different peptide families entirely: TA-1 is an alpha-thymosin studied in immune-signalling research, while TB-500 is synthetic thymosin beta-4, studied in tissue-repair and cell-migration research. They are not interchangeable in research designs.
What is the thymosin alpha-1 dosage?
We don’t provide protocols: this material is sold for laboratory research only, and published exposure data is specific to the authorized drug product sold abroad, not research vials.
Why did the US restrict compounded thymosin alpha-1?
After a 2024 advisory-committee review, the FDA declined to allow pharmacies to continue compounding TA-1, and it has never been an FDA-approved drug. That decision applies to the US compounding system; in Canada the compound was never available as a medicine, and its research-chemical status is unchanged.
For laboratory research use only. Not for human consumption. Not evaluated for approval by Health Canada. The information on this page summarises regulatory records and published research for educational purposes and is not medical advice.